Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03245827
Other study ID # 28389
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date April 1, 2019
Est. completion date October 29, 2021

Study information

Verified date June 2022
Source St. Louis University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Obesity can lead to low testosterone concentrations in young men. This study will study the effects of low testosterone in those men and the result of treating them with clomiphene.


Description:

The prevalence of obesity has increased in children over the past few decades. Approximately 20% of adolescent boys are now considered obese. It is well accepted that obese children are at increased risk for high blood pressure, lipid abnormalities and type 2 diabetes. Recent studies have uncovered yet another undesirable effect of obesity. The testosterone levels of obese boys are only half those of lean boys at completion of puberty. Testosterone is important for muscle and bone development. Men with low testosterone are at higher risk of insulin resistance and inflammation, which lead to type 2 diabetes and heart disease. Since testosterone is the major reproductive hormone, these obese boys are at risk of decreased fertility. Men are supposed to achieve their peak testosterone levels at puberty. Thereafter, there is a decline in testosterone levels at the rate of 2% per year for the rest of life. Thus there is a clear need to develop a deeper understanding of low testosterone in these males who are entering their peak fertility years. There are no approved treatments for this disorder. The investigators propose to conduct a randomized placebo controlled trial to evaluate the effect of treatment with clomiphene in obese young men(age 18-30 years) who have low testosterone concentrations. Clomiphene is a drug that increases testosterone concentrations and possibly increases sperm production. In contrast, testosterone replacement therapy decreased fertility and cannot be used in young men. Investigators will study the effect of treatment with clomiphene or placebo tablets for 12 weeks in 30 subjects. The study will evaluate:- 1. testicular function: Testosterone and two proteins secreted by testis(insulin like factor 3 and inhibin B) will be measured in the blood before and after treatment with clomiphene or placebo. 2. insulin resistance: Investigators will measure insulin and glucose levels in the blood. 3. inflammation: Investigators will measure proteins that induce inflammation.


Recruitment information / eligibility

Status Terminated
Enrollment 9
Est. completion date October 29, 2021
Est. primary completion date October 29, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria: - Males - Age 18-30 years inclusive will be recruited. A total of 90 males will be recruited:- - 30 obese males (defined as BMI =30 kg/m2) with HH, - 30 obese males with normal FT concentrations and - 30 lean males (defined as BMI <25 kg/m2) with normal FT concentrations. Exclusion Criteria: - Use of androgens, clomiphene, hCG, aromatase inhibitors or over the counter health supplements which contain androgens currently or in the past 6 months - Hematocrit > 50% - Congestive heart failure - currently suffering from depression - type 1 diabetes - Hepatic disease (transaminase > 3 times normal) or cirrhosis - Renal impairment (eGFR<30 ml/min/1.73m2) - HIV or Hepatitis C positive status - Participation in any other concurrent clinical trial - currently suffering from foot ulcer, significant periodontal disease or any other chronic infectious condition

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Clomiphene
clomiphene capsule 25mg twice a week
Placebo
placebo capsule 25mg twice a week

Locations

Country Name City State
United States Saint Louis Univeristy Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
Sandeep Singh Dhindsa, M.D., F.A.C.E

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serum Free Testosterone after clomiphene or placebo treatment 12 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04733274 - Patient and Healthcare Professional Views on Genetic/Genomic Information and Testing
Recruiting NCT04927676 - Hormones in Hypogonadotropic Hypogonadism
Recruiting NCT03490513 - Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism Phase 4